ALS-biomarkers

NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023

Staff Reporter November 6, 2023 0

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has completed dosing of the...

NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023

KW Delhi-6 Mall Joined Hands with Yashoda Healthcare to Spread Awareness on Breast Cancer

India’s reputation as the “Pharmacy to the World” is Potentially Under Threat Substandard Imports of IPA add to the Quality Burden

Sculpt Clinics Introduces New Laser Hair Removal Technology

HEAL Foundation Announces Healthcare CSR Summit & Awards in New Delhi

Apsara Ice Creams to launch Muskaan initiative on its 53rd anniversary

NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023

Interesting Stories For You

KW Delhi-6 Mall Joined Hands with Yashoda Healthcare to Spread Awareness on Breast Cancer

India’s reputation as the “Pharmacy to the World” is Potentially Under Threat Substandard Imports of IPA add to the Quality Burden

Sculpt Clinics Introduces New Laser Hair Removal Technology

HEAL Foundation Announces Healthcare CSR Summit & Awards in New Delhi

Apsara Ice Creams to launch Muskaan initiative on its 53rd anniversary